SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Akili, Inc. AKLI NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Akili, Inc. (AKLI) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $0.43. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is AKLI = $3 (+650.4% upside).

Financials: revenue is $2M, +97.7%/yr average growth. Net income is $59M (loss), growing at -233.7%/yr. Net profit margin is -3545.5% (negative). Gross margin is 51.2% (-38.2 pp trend).

Balance sheet: total debt is $15M against $59M equity (Debt-to-Equity (D/E) ratio 0.26, conservative). Current ratio is 6.02 (strong liquidity). Debt-to-assets is 19.3%. Total assets: $80M.

Analyst outlook: 2 / 4 analysts rate AKLI as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 35/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$3.25

▲ 650.4% Upside

Average Price Target

Based on 4 Wall Street analysts offering 12-month price targets for Akili, Inc., the average price target is $3.25, with a high forecast of $4.50, and a low forecast of $2.00.

Highest Price Target

$4.50

Average Price Target

$3.25

Lowest Price Target

$2.00

AKLI SharesGrow Score Overview

56/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 35/100

Gross margin is + market cap

FUTURE 64/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AKLI

AKLI trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $3, implying +592.7% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

AKLI: +97.7%/yr revenue is, -233.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet AKLI: Debt-to-Equity (D/E) ratio 0.26 (conservative), Current ratio is 6.02 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AKLI: Gross margin is 51.2% (-38.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 4 analysts rate AKLI as buy (50%). Analyst consensus target is $3 (+592.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

AKLI: Net profit margin is -3545.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.1912-1.25

Volume236.45K

Avg Volume (30D)2.3M

Market Cap$34.1M

Beta (1Y)1.73

Share Statistics

EPS (TTM)-0.76

Shares Outstanding$78.2M

IPO Date2021-06-30

Employees68

CEOMatthew Franklin

Financial Highlights & Ratios

Revenue (TTM)$1.68M

Gross Profit$859K

EBITDA$-60.14M

Net Income$-59.49M

Operating Income$-64.49M

Total Cash$75.46M

Total Debt$15.49M

Net Debt$-59.97M

Total Assets$80.38M

Price / Earnings (P/E)-0.6

Price / Sales (P/S)20.32

Analyst Forecast

1Y Price Target$3.25

Target High$4.50

Target Low$2.00

Upside+650.4%

Rating ConsensusBuy

Analysts Covering4

Buy 50% Hold 50% Sell 0%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS00974B1070

Price Chart

AKLI

Akili, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Healthcare Information Services

0.19 52WK RANGE 1.25

People Also View

HealthEquity, Inc.

NextGen Healthcare, Inc.

HealthStream, Inc.

National Research Corporation

Computer Programs and Systems, Inc.

Health Catalyst, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message